This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ogawa, M. Articles by Hamaoka, T. Search for Related Content PubMed PubMed Citation Articles by Ogawa, M. Articles by Hamaoka, T.

Enhanced Induction of Very Late Antigen 4/Lymphocyte Function-associated Antigen 1-dependent T-Cell Migration to Tumor Sites following Administration of Interleukin 12¹

Biomedical Research Center [M. O., T. T., J-P. Z. J. M., R. W., W-G. Y., H. F., T. H.] and Department of Otorhinolaryngology [T. K.], Osaka University Medical School, 2-2 Yamada-oka, Suita, Osaka 565, Japan and Genetics Institute, Inc., Cambridge, Massachusetts 02140 [S. H.]

Administration of interleukin 12 (IL-12) into mice bearing CSA1M, OV-HM, Meth A, or MCH-1-A1 tumor induced complete regression of CSA1M and OV-HM tumors but induced only a slight growth inhibition of Meth A and MCH-1-A1 tumors. These effects of IL-12 were associated with high and only marginal levels of T-cell infiltration into CSA1M/OV-HM and Meth A/MCH-1-A1 tumor masses, respectively. Here, we investigated the role of IL-12 in the induction of T-cell migration. Spleen cells from untreated or IL-12-treated CSA1M-bearing mice were stained in vitro with a fluorescein chemical and transferred i.v. into IL-12-untreated CSA1M-bearing mice. Migration of donor cells was quantitated by counting the number of fluorescent cells on cryostat sections of tumor masses. Although only a slight migration was detected for spleen cells from IL-12-untreated CSA1M-bearing as well as IL-12-treated or untreated normal mice, enhanced migration was observed for cells from IL-12-treated CSA1M-bearing mice. A similar enhanced migration was observed for the OV-HM model. In contrast, such an enhancement was only marginal in the Meth A and MCH-1-A1 models. Immunohistochemical studies of tumors from IL-12-treated mice revealed that the predominant T-cell subset was CD4⁺ in CSA1M and CD8⁺ in OV-HM tumor masses. Consistent with this observation, the dominant subset of migrating T cells was found to be CD4⁺ in the CSA1M and CD8⁺ in the OV-HM models. T-cell migration was inhibited by pretreatment of recipients with either combination of anti-very late antigen 4 + anti-vascular cell adhesion molecule 1 or anti-lymphocyte function-associated antigen 1 + antiintercellular adhesion molecule 1 monoclonal antibody. These results indicate that IL-12 can confer T cells with a capacity to migrate to tumor sites through very late antigen 4/lymphocyte function-associated antigen 1 adhesion pathways and that the in vivo acquisition of such a capacity following IL-12 treatment correlates with the induction of tumor regression.

¹ This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Culture, Japan.

² To whom requests for reprints should be addressed. Phone: 81-06-879-3982; Fax: 81-06-879-3989.

Received 12/10/96. Accepted 4/ 3/97.

This article has been cited by other articles:

				T. F. Gajewski Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment Clin. Cancer Res., September 15, 2007; 13(18): 5256 - 5261. [Abstract] [Full Text] [PDF]

				R. Ohta, N. Kondor, N. Dohi, S. Tomlinson, M. Imai, V. M. Holers, H. Okada, and N. Okada Mouse Complement Receptor-Related Gene y/p65-Neutralized Tumor Vaccine Induces Antitumor Activity In Vivo J. Immunol., July 1, 2004; 173(1): 205 - 213. [Abstract] [Full Text] [PDF]

				Y. Uekusa, P. Gao, N. Yamaguchi, M. Tomura, T. Mukai, C. Nakajima, M. Iwasaki, N. Takeuchi, T. Tsujimura, M. Nakazawa, et al. A role for endogenous IL-12 in tumor immunity: IL-12 is required for the acquisition of tumor-migratory capacity by T cells and the development of T cell-accepting capacity in tumor masses J. Leukoc. Biol., November 1, 2002; 72(5): 864 - 873. [Abstract] [Full Text] [PDF]

				R. A. Wilcox, D. B. Flies, H. Wang, K. Tamada, A. J. Johnson, L. R. Pease, M. Rodriguez, Y. Guo, and L. Chen Impaired Infiltration of Tumor-specific Cytolytic T Cells in the Absence of Interferon-{gamma} despite Their Normal Maturation in Lymphoid Organs during CD137 Monoclonal Antibody Therapy Cancer Res., August 1, 2002; 62(15): 4413 - 4418. [Abstract] [Full Text] [PDF]

				Y. Uekusa, W.-G. Yu, T. Mukai, P. Gao, N. Yamaguchi, M. Murai, K. Matsushima, S. Obika, T. Imanishi, Y. Higashibata, et al. A Pivotal Role for CC Chemokine Receptor 5 in T-Cell Migration to Tumor Sites Induced by Interleukin 12 Treatment in Tumor-bearing Mice Cancer Res., July 1, 2002; 62(13): 3751 - 3758. [Abstract] [Full Text] [PDF]

				T. M. Carlos Leukocyte recruitment at sites of tumor: dissonant orchestration J. Leukoc. Biol., August 1, 2001; 70(2): 171 - 184. [Abstract] [Full Text] [PDF]

				H. Irjala, M. Salmi, K. Alanen, R. Grenman, and S. Jalkanen Vascular Adhesion Protein 1 Mediates Binding of Immunotherapeutic Effector Cells to Tumor Endothelium J. Immunol., June 1, 2001; 166(11): 6937 - 6943. [Abstract] [Full Text] [PDF]

				C. Nakajima, Y. Uekusa, M. Iwasaki, N. Yamaguchi, T. Mukai, P. Gao, M. Tomura, S. Ono, T. Tsujimura, H. Fujiwara, et al. A Role of Interferon-{{gamma}} (IFN-{{gamma}}) in Tumor Immunity: T Cells with the Capacity to Reject Tumor Cells Are Generated But Fail to Migrate to Tumor Sitesin IFN-{{gamma}}-deficient Mice Cancer Res., April 1, 2001; 61(8): 3399 - 3405. [Abstract] [Full Text]

				E. J. Roy, U. Gawlick, B. A. Orr, L. A. Rund, A. G. Webb, and D. M. Kranz IL-12 Treatment of Endogenously Arising Murine Brain Tumors J. Immunol., December 15, 2000; 165(12): 7293 - 7299. [Abstract] [Full Text] [PDF]

				R. Mortarini, A. Borri, G. Tragni, I. Bersani, C. Vegetti, E. Bajetta, S. Pilotti, V. Cerundolo, and A. Anichini Peripheral Burst of Tumor-specific Cytotoxic T Lymphocytes and Infiltration of Metastatic Lesions by Memory CD8+ T Cells in Melanoma Patients Receiving Interleukin 12 Cancer Res., July 1, 2000; 60(13): 3559 - 3568. [Abstract] [Full Text]

				M. Iwasaki, W.-G. Yu, Y. Uekusa, C. Nakajima, Y.-F. Yang, P. Gao, R. Wijesuriya, H. Fujiwara, and T. Hamaoka Differential IL-12 responsiveness of T cells but not of NK cells from tumor-bearing mice in IL-12-responsive versus -unresponsive tumor models Int. Immunol., May 1, 2000; 12(5): 701 - 709. [Abstract] [Full Text] [PDF]

				K. Boggio, E. Di Carlo, S. Rovero, F. Cavallo, E. Quaglino, P. L. Lollini, P. Nanni, G. Nicoletti, S. Wolf, P. Musiani, et al. Ability of Systemic Interleukin-12 to Hamper Progressive Stages of Mammary Carcinogenesis in HER2/neu Transgenic Mice Cancer Res., January 1, 2000; 60(2): 359 - 364. [Abstract] [Full Text]

				L. Colantonio, A. Iellem, B. Clissi, R. Pardi, L. Rogge, F. Sinigaglia, and D. D'Ambrosio Upregulation of Integrin alpha 6/beta 1 and Chemokine Receptor CCR1 by Interleukin-12 Promotes the Migration of Human Type 1 Helper T Cells Blood, November 1, 1999; 94(9): 2981 - 2989. [Abstract] [Full Text] [PDF]

				C. S. Schmidt and M. F. Mescher Adjuvant Effect of IL-12: Conversion of Peptide Antigen Administration from Tolerizing to Immunizing for CD8+ T Cells In Vivo J. Immunol., September 1, 1999; 163(5): 2561 - 2567. [Abstract] [Full Text] [PDF]

				M. Ogawa, K. Umehara, W.-G. Yu, Y. Uekusa, C. Nakajima, T. Tsujimura, T. Kubo, H. Fujiwara, and T. Hamaoka A Critical Role for a Peritumoral Stromal Reaction in the Induction of T-Cell Migration Responsible for Interleukin-12-induced Tumor Regression Cancer Res., April 1, 1999; 59(7): 1531 - 1538. [Abstract] [Full Text] [PDF]

				F. Cavallo, E. D. Carlo, M. Butera, R. Verrua, M. P. Colombo, P. Musiani, and G. Forni Immune Events Associated with the Cure of Established Tumors and Spontaneous Metastases by Local and Systemic Interleukin 12 Cancer Res., January 1, 1999; 59(2): 414 - 421. [Abstract] [Full Text] [PDF]

				C. S. Constantinescu, M. Wysocka, B. Hilliard, E. S. Ventura, E. Lavi, G. Trinchieri, and A. Rostami Antibodies Against IL-12 Prevent Superantigen-Induced and Spontaneous Relapses of Experimental Autoimmune Encephalomyelitis J. Immunol., November 1, 1998; 161(9): 5097 - 5104. [Abstract] [Full Text] [PDF]